Addition of pTau217 test further expands the
company's leadership in testing options for Alzheimer's disease to
improve patient care
BURLINGTON, N.C., March 20,
2024 /PRNewswire/ -- Labcorp (NYSE: LH), a
global leader of innovative and comprehensive laboratory services,
announced today the launch and immediate availability of its test
to identify the presence or absence of phosphorylated tau 217
(pTau217), a pivotal blood biomarker designed to aid in the
diagnosis of Alzheimer's disease and the subsequent monitoring of
patients undergoing treatment with new Alzheimer's disease
therapies. Labcorp's pTau217 test can be ordered by physicians and
used in clinical trials and research by global biopharmaceutical
partners.
Alzheimer's disease, the most prevalent form of dementia, poses
a significant health challenge globally. An estimated 6.7 million
Americans are currently living with Alzheimer's disease, a figure
projected to more than double to 13.8 million individuals by 2060.
The pTau217 marker has been used in Alzheimer's drug trials to
monitor patients on anti-amyloid therapy.
Labcorp's introduction of pTau217 as a standalone test marks a
significant advancement in the company's Alzheimer's testing
portfolio, complementing its existing array of blood-based
biomarker testing, including:
- Beta amyloid 42/40 ratio, which provides an indication of
amyloid pathology for Alzheimer's disease and is available
nationwide for clinicians and available in Europe as a CE-marked assay.
- Neurofilament light chain (NfL), which provides an indication
of disease severity by measuring current levels of
neurodegeneration.
- ATN Profile, which combines three blood biomarkers – beta
amyloid 42/40, NfL and pTau181. The ATN Profile provides physicians
with an accessible and interpretable blood test to assess
pathologies associated with Alzheimer's disease and other
neurodegenerative conditions, which can help accelerate the path to
diagnosis and intervention.
"The introduction of pTau217 represents a significant milestone
in our ongoing commitment to advancing testing capabilities across
the spectrum of Alzheimer's disease," said Dr. Brian
Caveney, Labcorp's Chief Medical and Scientific Officer.
"By expanding our suite of blood-based biomarker tests, we are
empowering clinicians and pharma with more tools for clinical
trials and for the detection and monitoring of Alzheimer's to
improve patient care."
For more information about the pTau217 biomarker and the use of
Labcorp's new test in patient care, visit
http://www.labcorp.com/alzheimers.
For biopharma laboratory services inquiries, please visit
https://www.labcorp.com/neurology/neurodegenerative-diseases/pharmaceutical-partners.
About Labcorp
Labcorp (NYSE: LH) is a global leader of
innovative and comprehensive laboratory services that helps
doctors, hospitals, pharmaceutical companies, researchers and
patients make clear and confident decisions. We provide insights
and advance science to improve health and improve lives through our
unparalleled diagnostics and drug development laboratory
capabilities. The company's more than 67,000 employees serve
clients in over 100 countries, worked on over 84% of the new drugs
approved by the FDA in 2023 and performed more than 600 million
tests for patients around the world. Learn more about us at
www.labcorp.com.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/labcorp-launches-ptau217-blood-biomarker-test-to-accelerate-path-to-diagnosis-of-alzheimers-disease-and-support-clinical-trials-302094433.html
SOURCE Labcorp